stockrow
Wednesday 11 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
13.12
0.03
−0.23%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) EBITDA
Vir Biotechnology, Inc.'s EBITDA for fiscal 2025 was −$458.2M, compared with −$567.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$198.6M. Over the past ten years it has ranged from −$673.6M (fiscal 2023) to $830.9M (fiscal 2022); the current reading is higher than 33% of that period. Vir Biotechnology, Inc. ranks 513th of 596 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$458.2M | — |
| FY2024 | −$567.2M | — |
| FY2023 | −$673.6M | — |
| FY2022 | $830.9M | 94.90% |
| FY2021 | $426.3M | — |
| FY2020 | −$289.2M | — |
| FY2019 | −$173.6M | — |
| FY2018 | −$116.3M | — |
| FY2017 | −$81.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$102.6M | — |
| Jun 2026 | $76.6M | — |
| Mar 2026 | −$129.1M | — |
| Dec 2025 | −$43.5M | — |
| 28 more quarters | Free account |
Against its own ten years
Low −$673.6M
High $830.9M
Ten-year median
−$173.6M
Current reading's percentile
33
EBITDA against peers
| Company | EBITDA |
|---|---|
| ZYME Zymeworks Inc. compare | $53.8M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. | −$198.6M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| REPL Replimune Group, Inc. compare | −$266.7M |
| IMNM Immunome, Inc. compare | −$298.0M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on VIR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement